41. |
42. Priporočila za obravnavo bolnic z rakom zunanjega spolovilaSebastjan Merlo, Nina Kovačević, Barbara Šegedin, Tina Arnež, Sonja Bebar, Barbara Gazić, Andreja Gornjec, Borut Kobal, Manja Šešek, Maja Pakiž, Erik Škof, Iztok Takač, Vesna Zadnik, Helena Barbara Zobec Logar, 2020, strokovni članek Ključne besede: zunanje spolovilo, rak (medicina), diagnostika, zdravljenje
Objavljeno v DiRROS: 07.04.2021; Ogledov: 1283; Prenosov: 475
 Celotno besedilo (745,40 KB)
Gradivo ima več datotek! Več... |
43. Priporočila za obravnavo bolnic z rakom zunanjega spolovilaSebastjan Merlo, Nina Kovačević, Barbara Šegedin, Tina Arnež, Sonja Bebar, Barbara Gazić, Andreja Gornjec, Borut Kobal, Manja Šešek, Maja Pakiž, Erik Škof, Iztok Takač, Vesna Zadnik, Helena Barbara Zobec Logar, 2020, strokovni članek Ključne besede: zunanje spolovilo, rak (medicina), diagnostika, zdravljenje
Objavljeno v DiRROS: 18.03.2021; Ogledov: 1217; Prenosov: 392
Celotno besedilo (745,40 KB) |
44. Immunohistochemistry of pulmonary biomarkers : a perspective from members of the pulmonary pathology societyErik Thunnissen, Timothy Craig Allen, Julien Adam, Dara L. Aisner, Mary Beth Beasley, Alain C. Borczuk, Philip T. Cagle, Vera Luiza Capelozzi, Wendy Cooper, Izidor Kern, 2018, izvirni znanstveni članek Povzetek: The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK, (ROS1, EGFR in Europe), and programmed death ligand-1 (PD-L1) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes.
Ključne besede: pulmonary biomarkers, immunohistochemistry, pathology
Objavljeno v DiRROS: 17.12.2020; Ogledov: 1126; Prenosov: 409
 Povezava na datoteko |
45. Comparison of European ICU patients in 2012 (ICON) versus 2002 (SOAP)Jean Louis Vincent, Jean-Yves Lefrant, Katarzyna Kotfis, Rahul Nanchal, Ignacio Martin-Loeches, Samir G. Sakka, Xavier Wittebole, Peter Pickkers, Rui P. Moreno, Yasser Sakr, 2018, izvirni znanstveni članek Povzetek: Purpose: To evaluate differences in the characteristics and outcomes of intensive care unit (ICU) patients over time. Methods: We reviewed all epidemiological data, including comorbidities, types and severity of organ failure, interventions, lengths of stay and outcome, for patients from the Sepsis Occurrence in Acutely ill Patients (SOAP) study, an observational study conducted in European intensive care units in 2002, and the Intensive Care Over Nations (ICON) audit, a survey of intensive care unit patients conducted in 2012. Results: We compared the 3147 patients from the SOAP study with the 4852 patients from the ICON audit admitted to intensive care units in the same countries as those in the SOAP study. The ICON patients were older (62.5 +/- 17.0 vs. 60.6 +/- 17.4 years) and had higher severity scores than the SOAP patients. The proportion of patients with sepsis at any time during the intensive care unit stay was slightly higher in the ICON study (31.9 vs. 29.6%, p = 0.03). In multilevel analysis, the adjusted odds of ICU mortality were significantly lower for ICON patients than for SOAP patients, particularly in patients with sepsis [OR 0.45 (0.35-0.59), p < 0.001]. Conclusions: Over the 10-year period between 2002 and 2012, the proportion of patients with sepsis admitted to European ICUs remained relatively stable, but the severity of disease increased. In multilevel analysis, the odds of ICU mortality were lower in our 2012 cohort compared to our 2002 cohort, particularly in patients with sepsis.
Ključne besede: intensive care units -- analysis -- epidemiology -- mortality, sepsis, severity of disease
Objavljeno v DiRROS: 30.11.2020; Ogledov: 1618; Prenosov: 1117
Celotno besedilo (867,51 KB)
Gradivo ima več datotek! Več... |
46. The clinical relevance of oliguria in the critically ill patient : analysis of a large observational databaseJean Louis Vincent, Andrew Ferguson, Peter Pickkers, Stephan M. Jakob, Ulrich Jaschinski, Ghaleb A. Almekhlafi, Marc Leone, Majid Mokhtari, Luis E. Fontes, Philippe R. Bauer, Yasser Sakr, 2020, izvirni znanstveni članek Povzetek: Background: Urine output is widely used as one of the criteria for the diagnosis and staging of acute renal failure, but few studies have specifically assessed the role of oliguria as a marker of acute renal failure or outcomes in general intensive care unit (ICU) patients. Using a large multinational database, we therefore evaluated the occurrence of oliguria (defined as a urine output < 0.5 ml/kg/h) in acutely ill patients and its association with the need for renal replacement therapy (RRT) and outcome. Methods: International observational study. All adult (> 16 years) patients in the ICON audit who had a urine output measurement on the day of admission were included. To investigate the association between oliguria and mortality, we used a multilevel analysis. Results: Of the 8292 patients included, 2050 (24.7%) were oliguric during the first 24 h of admission. Patients with oliguria on admission who had at least one additional 24-h urine output recorded during their ICU stay (n = 1349) were divided into three groups: transient-oliguria resolved within 48 h after the admission day (n = 390 [28.9%]), prolonged-oliguria resolved > 48 h after the admission day (n = 141 [10.5%]), and permanent-oliguria persisting for the whole ICU stay or again present at the end of the ICU stay (n = 818 [60.6%]). ICU and hospital mortality rates were higher in patients with oliguria than in those without, except for patients with transient oliguria who had significantly lower mortality rates than non-oliguric patients. In multilevel analysis, the need for RRT was associated with a significantly higher risk of death (OR = 1.51 [95% CI 1.19%1.91], p = 0.001), but the presence of oliguria on admission was not (OR = 1.14 [95% CI 0.97%1.34], p = 0.103). Conclusions: Oliguria is common in ICU patients and may have a relatively benign nature if only transient. The duration of oliguria and need for RRT are associated with worse outcome.
Ključne besede: critical care, critical illness, urine, oliguria, kidney, renal insufficiency, kidney diseases, acute kidney failure, mortality, urine output, renal replacement therapy
Objavljeno v DiRROS: 18.11.2020; Ogledov: 1598; Prenosov: 1015
Celotno besedilo (727,74 KB)
Gradivo ima več datotek! Več... |
47. Lung cancer biomarker testing : perspective from EuropeErik Thunnissen, Birgit Weynand, Dalma Udovicic-Gagula, Luka Brčić, Malgorzata Szolkowska, Paul Hofman, Silvana Smojver-Ježek, Sisko Anttila, Fiorella Calabrese, Izidor Kern, 2020, pregledni znanstveni članek Povzetek: A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26-28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long-term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future.
Ključne besede: lung neoplasms -- diagnosis -- therapy -- Europe, lung cancer, predictive testing
Objavljeno v DiRROS: 21.09.2020; Ogledov: 1609; Prenosov: 1046
Celotno besedilo (1,80 MB)
Gradivo ima več datotek! Več... |
48. Naše izkušnje z zdravilom bevacizumab v primarnem zdravljenju epitelijskega raka jajčnikovErik Škof, Dushan Mangaroski, 2020, izvirni znanstveni članek Povzetek: Izhodišče: Zdravilo bevacizumab uporabljamo v sklopu primarnega sistemskega zdravljenja napredovalega epitelijskega raka jajčnikov v kombinaciji s paklitakselom in karboplatinom od leta 2013.
Namen: Prikazati učinkovitost in varnost zdravljenja z bevacizumabom v redni klinični praksi v sklopu primarnega zdravljenja raka jajčnikov.
Metode: V retrospektivno analizo smo vključili bolnice z epitelijskim rakom jajčnikov, ki so se zdravile z bevacizumabom na Onkološkem inštitutu Ljubljana v obdobju od 1. 1. 2013 do 31. 12. 2016. Cilja raziskave sta bila varnost in učinkovitost (preživetje brez ponovitve bolezni, celokupno preživetje) zdravljenja z bevacizumabom. Raziskavo je odobrila etična komisija na Onkološkem inštitutu Ljubljana.
Rezultati: V opazovanem obdobju je bilo z bevacizumabom zdravljenih 111 bolnic z napredovalim epitelijskim rakom jajčnikov. Najpogostejši neželeni učinki so bili: bolečine (52 %), krvavitev (45 %), arterijska hipertenzija (44 %). Resne neželene učinke (stopnja 3/4) je imelo 12 % bolnic: venska tromboza/ embolija (3 %), proteinurija (3 %), arterijska hipertenzija (2 %), krvavitev (2 %), bolečine (1 %), fistula (1 %). Mediani čas sledenja je bil 59 mesecev. Mediano preživetje brez ponovitve bolezni je bilo 18 mesecev, mediano celokupno preživetje pa 41 mesecev.
Zaključki: Zdravljenje z bevacizumabom v redni klinični praksi je varno in učinkovito ‒ v skladu z do zdaj znanimi rezultati prospektivnih raziskav GOG 218 in ICON 7.
Ključne besede: rak jajčnikov, epitelijski rak, bevacizumab, kemoterapija
Objavljeno v DiRROS: 09.09.2020; Ogledov: 1873; Prenosov: 501
Celotno besedilo (173,87 KB) |
49. Rak trebušne slinavke : kaj morate vedeti o bolezni?Janja Ocvirk, Martina Reberšek, Zvezdana Hlebanja, Erik Škof, Irena Oblak, Vaneja Velenik, Franc Anderluh, 2008, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: dejavniki tveganja, simptomi, diagnostika, zdravljenje, bolečina
Objavljeno v DiRROS: 10.08.2020; Ogledov: 1695; Prenosov: 683
Celotno besedilo (1,52 MB) |
50. Postopki za obravnavo bolnic z rakom materničnega vratuBarbara Šegedin, Sonja Bebar, Olga Cerar, Branko Cvjetičanin, Barbara Gazić, Brigita Gregorič, Urška Ivanuš, Borut Kobal, Manja Šešek, Leon Meglič, Maja Pakiž, Nina Kovačević, Špela Smrkolj, Erik Škof, Iztok Takač, Helena Barbara Zobec Logar, 2019, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: ONKOLOGIJA-STOJIŠČE, onkologija, ginekologija
Objavljeno v DiRROS: 10.06.2020; Ogledov: 1779; Prenosov: 556
Celotno besedilo (717,48 KB) |
